Pierre Gholam, MD, discusses his thoughts on a phase 3 trial which evaluated camrelizumab plus rivoceranib vs sorafenib in the first-line for patients with unresectable hepatocellular carcinoma.
Pierre Gholam, MD, professor at Case Western Reserve University School of Medicine in Cleveland, Ohio, discusses his thoughts on a trial (NCT03764293) which evaluated camrelizumab (AiRuiK) and rivoceranib vs sorafenib (Nexavar) in the first-line for patients with unresectable hepatocellular carcinoma (HCC).
In the phase 3 study, the PD-1 inhibitor camrelizumab was combined with the VEGFR2 tyrosine kinase inhibitor (TKI) rivoceranib. Findings showed that this combination significantly improved progression-free and overall survival vs treatment with sorafenib among patients with HCC.
Regarding safety, the combination was generally well-tolerated, and the safety profile was in line with each individual agent and the underlying disease.
TRANSCRIPTION:
0:08 | This was a study primarily from China where these 2 agents are compared to sorafenib. In the setting, the combination achieved the median overall survival of 22.1 months vs 15.2 months for sorafenib. I think it's notable that the baseline characteristics of the patients included a very strong emphasis on patients whose liver disease was driven by hepatitis B. About roughly 76% of the patients had hepatitis B.
0:48 | Aside from that, the overall characteristics of the patients were fairly similar to what one would expect in a first-time study. The objective response rate for the combination was 25.4 months and for sorafenib alone, it was 5.9 months.
1:08 | The adverse events that were reported were fairly on par with what one would expect in the setting of a combination of an immune checkpoint inhibitor and TKI. I think that the conclusion from all the data that we reported in this study is that this may be a viable combination, certainly in the subset of patients with hepatitis B driven disease. We'll see whether this combination takes its way through the regulatory process towards potential approval in the [United States] and Northern Europe.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More